

Second Annual Multidisciplinary Endocrine Tumor Symposium

"Mild Autonomous Cortisol Secretion and Primary Aldosteronism"

Friday, June 24, 2022

Virtual Conference via Zoom

**Sponsored by the UT Southwestern Department of Endocrine Surgery
and the UT Southwestern Office of Continuing Medical Education**

PURPOSE AND CONTENT

Target Audience

Physicians, nurses, and healthcare professionals in the specialties of surgery, endocrinology, medical oncology, radiation oncology, and medical oncology.

Professional Practice Gap

The guidelines and clinical management of autonomous cortisol production and aldosterone production by the adrenal glands have evolved significantly over the past several years. For example, the biochemical diagnosis, investigation and subsequent treatment recommendations for a complex spectrum of patients continues to evolve. Ever-changing guidelines plus multiple different specialty providers involved in the treatment of adrenal patients (particularly where surgeons, endocrinologists and primary care providers may be primarily responsible for any given patient) increases inconsistencies and confusion in optimal care which negatively impacts patient outcomes.

Educational Need

Evaluate current and evolving guidelines in the work up and clinical management of patients with autonomous cortisol secretion and primary hyperaldosteronism with respect to: A. Specifics of biochemical diagnosis; B. Utility of Adrenal Vein Sampling; and C. Selection of patients for surgery vs medical management/monitoring.

Educational Objectives

- 1) Interpret current and evolving treatment guidelines and best practices for biochemical diagnosis;
- 2) Discuss current and emerging investigative imaging and interventional studies; and
- 3) Identify recommendations for surgical vs. medical management.

Desired Result

Expanded application of treatment guidelines and expert recommendations by the healthcare team to ensure data driven, standard of care is being administered to promote best patient outcomes.

FACULTY

Course Directors/Moderators

Alan Dackiw, M.D., Ph.D., M.B.A

Professor, Department of Surgery
Division of Endocrine Surgery
UT Southwestern Medical Center
Dallas, TX

Oksana Hamidi, D.O.

Assistant Professor,
Division of Endocrinology and Metabolism
UT Southwestern Medical Center
Dallas, TX

Guest Speakers

Richard J. Auchus, M.D., Ph.D., FACE

James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine
Professor of Pharmacology and Internal Medicine,
Division of Metabolism, Endocrinology, & Diabetes
University of Michigan
Chief, Endocrinology Section, LTC Charles S. Kettles VA Medical Center
Ann Arbor, MI

Irina Bancos, M.D.

Associate Professor of Medicine
Division of Endocrinology, Diabetes, Metabolism, Nutrition
Department of Internal Medicine
Mayo Clinic
Rochester, MN

ACCREDITATION AND DESIGNATION STATEMENTS

Accreditation

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Physicians

The University of Texas Southwestern Medical Center at Dallas designates this continuing education activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Each physician should claim only the credit commensurate with the extent of the participation in the activity.

Non-Physicians

The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for a maximum of 3.0 AMA PRA Category 1 Credits™.

EVALUATIONS AND CERTIFICATES

CME Certificates (Physicians) and Certificates of Attendance (Non-Physicians) are available online after the electronic evaluation is completed. This evaluation is an important tool for assessing the effectiveness of this activity as well as for planning future activities.

Next week, all attendees will receive an email with a link to access the evaluation. Once the evaluation is completed, attendance can claim credit (CME, Attendance) and view/download/print certificate.

DISCLAIMER

This symposium has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the symposium format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.

DISCLOSURE OF UNLABELED USES

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians' Desk Reference.

DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

It is the policy of the CME Office at The University of Texas Southwestern Medical Center to ensure balance, independence, objectivity, and scientific rigor in all directly sponsored or jointly provided educational activities. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company (any entity whose primary business is producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients).

UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies.

All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).

(continues on next page)

The following is a listing of all individuals that contributed to the educational content of this activity and any reported financial relationships within the last 24 months:

Name	Role	Financial Relationship Disclosed
Alan Dackiw, M.D., Ph.D., M.B.A.	Course Director Moderator	None
Oksana Hamidi, D.O.	Course Director Moderator	<u>Professional Services (Scientific Advisory Board):</u> Amryt Novo Nodrisk StrongBridge Recordati Rare Diseases
Richard J. Auchus, M.D., Ph.D., FACE	Speaker	<u>Grant Or Contract</u> Spruce Biosciences Neurocrine Biosciences Novartis Pharmaceuticals Diurnal, LTD Corcept Therapeutics <u>Independent contractor</u> Corcept Therapeutics Adrenas Therapeutics H Lundbeck A/S Quest Diagnostics Strongbridge Biopharma Xeris Pharmaceuticals Recordati Rare Diseases Novartis Pharmaceuticals PhaseBio Pharmaceuticals Janssen Pharmaceuticals Crinetics Pharmaceuticals OMass Pharmaceuticals
Irina Bancos, M.D	Speaker	<u>Consultant:</u> Sparrow Spruce Corcept HRA Pharma Recordati Lantheus Adrenas <u>Resarching Funding:</u> NIH NDDK <u>Other:</u> Elsevier point of care - writer Dynamed - reviewer
Gabby Hernandez	Planner	None
Mark Vinciguerra	CME Coordinator	None

SECOND ANNUAL UT SOUTHWESTERN ENDOCRINE TUMOR SYMPOSIUM

FRIDAY, JUNE 24, 2022

AGENDA

- 12:45 PM ***Participants to join Zoom***
- 12:55 PM ***Welcome & Introductions***
- 1:00 PM ***“Mild Autonomous Cortisol Secretion”***
 – Irina Bancos, M.D.
- 1:45 PM ***Question & Answer Session***
- 2:00 PM ***“A Rational Approach to the Occult Epidemic of Primary Aldosteronism”***
 – Richard J. Auchus, M.D., Ph.D., FACE
- 2:45 PM ***Question & Answer Session***
- 3:00 PM ***Clinical Case Presentations***
- 3:55 PM ***Closing Remarks***
- 4:00 PM ***Adjourn***
-